Vertigenius’s €80B TAM Is a Big Bet on a Niche Problem—But the Data Says It Might Not Be So Niche

I stumbled on this piece from Medhabi Ghosh at CB Insights about Vertigenius, and it’s one of those interviews that feels like a Rorschach test for digital health founders. If you read it as a niche play in vestibular therapy, you’ll shrug and scroll past. If you read it as a case study in how specialization beats generalization in remote patient monitoring, it gets a lot more interesting.

Mark Barry, the CEO, lays out a classic land-and-expand story: 390 million people need vestibular therapy, a €80 billion global TAM, but a €1 billion beachhead in US vestibular clinics. The pitch is that clinicians can’t oversee home-based vestibular treatment today, and Vertigenius fixes that while unlocking insurance reimbursement.

That’s a tidy narrative. But the numbers deserve a hard look, and the story around them deserves a wider lens.

The TAM Problem: Big Numbers, Small Evidence

The €80 billion TAM and the 390 million annual therapy figure are both unverifiable from public sources. That doesn’t make them wrong—private market sizing often leans on proprietary claims or internal modeling—but it does mean we should treat them as directional, not gospel. For an indie hacker or early-stage investor, the more useful question isn’t “is the TAM really €80 billion?” It’s “what’s the wedge that gets you to revenue before the TAM matters?”

Vertigenius is smart to orient toward the US first. Reimbursement pathways are clearer there than in Europe, and the beachhead of medium-to-large vestibular clinics is a concrete, salesable segment. That’s the kind of focus that wins in a fragmented healthcare market—if the product can prove clinical value and billing efficiency quickly.

But here’s what the CB Insights interview doesn’t ask: what does the actual day-to-day look like for the clinicians they’re selling to? Because that’s where adoption either happens or dies.

The Data Says the Real Pain Is Broader Than Vertigo

PainSignal tracks 814 distinct problems in healthcare, and many of them cluster around two things: remote monitoring gaps and documentation burden. That’s not specific to vestibular therapy. That’s across nursing, hospital systems, and outpatient clinics.

Consider this: problems like “Nurses lack real-time, independent verification of high-risk IV infusion rate changes” and “Nurse placed on unpaid administrative leave due to discrepancies between manually documented blood sugar records and glucometer audit trails” keep showing up. Those aren’t vertigo-specific. They’re symptoms of an industry that still can’t reliably bridge the gap between what happens with a patient at home and what gets recorded in a chart.

Vertigenius’s core pitch—clinicians can’t oversee home treatment—is a real gap. But it’s not an absolute gap. PainSignal data shows telehealth and remote monitoring tools are already being adopted, but often in clunky, non-integrated ways. The problem isn’t that remote oversight is impossible. It’s that it’s fragmented, poorly integrated with EHRs, and often a manual headache for clinicians.

That’s the opportunity hidden inside the niche. If Vertigenius can build a remote monitoring platform that doesn’t just work for vestibular therapy but does it with dead-simple documentation and automatic billing, they’re not just solving vertigo. They’re solving the same problem that plagues cardiac rehab, post-surgical follow-up, and a dozen other rehab-heavy specialties.

Reimbursement Is the Real Moat—and the Real Risk

The CEO’s claim that Vertigenius enables full insurance reimbursement is the linchpin. Without it, the product is a nice-to-have. With it, it’s a must-have.

But reimbursement is never a product feature; it’s a market condition. And it varies wildly by payer, state, and even clinic size. The interview glosses over this, and that’s a yellow flag. Founders who promise “fully reimbursed with insurance reimbursement revenue” are either sitting on exceptional payer contracts or they’re narrating a future state as if it’s current.

From an investor’s perspective, the first thing to verify isn’t the TAM. It’s whether Vertigenius has at least one or two live reimbursement pathways already working. If yes, the niche is a feature, not a bug. If no, the €80 billion TAM is just a number in a pitch deck.

Integration Will Make or Break the Wedge

The other missing piece in the CB Insights interview is EHR integration. PainSignal data keeps showing that healthcare problems often stem from poor system integration—duplicate documentation, missed alerts, mismatched records. If Vertigenius’s remote monitoring data doesn’t flow seamlessly into the clinic’s existing EHR, clinicians won’t use it. They’ll see it as one more login, one more dashboard, one more thing to check at the end of a long day.

Vertigenius might already have this solved. But the interview doesn’t say so, and in digital health, silence on integration is almost as concerning as silence on reimbursement. The best remote monitoring tools don’t create new workflows; they disappear into existing ones. That’s the bar.

What This Means for Builders and Investors

If you’re an indie hacker looking at healthcare remote monitoring, Vertigenius is a useful reference point: pick a narrow clinical domain, solve the supervision gap, and make documentation automatic. The market doesn’t need another generic telehealth app. It needs vertical tools that understand the specific constraints of vestibular therapy, wound care, cardiac rehab, or diabetes management.

If you’re an agency dev serving healthcare clients, the Vertigenius story is a reminder that the real pain isn’t always the headline problem. The headline is “remote monitoring.” The actual pain is “remote monitoring plus documentation plus billing without adding 20 minutes to a clinician’s day.” Build for that combo, and you’ll have a line out the door.

If you’re a seed investor, the question isn’t whether vestibular therapy is a €80 billion market. It’s whether the team can prove that their remote oversight tool saves clinicians time and captures revenue in a way that’s portable across adjacent rehab specialties. If the wedge is real, the TAM expands. If the wedge is fuzzy, the TAM is a vanity metric.

The Bottom Line

Vertigenius is betting on a narrow beachhead with a broad problem underneath. That’s a smart structure. But the CB Insights interview leaves the most important questions unanswered: Is reimbursement already working? Does the platform integrate with major EHRs? Does it actually reduce documentation time, not just add oversight?

PainSignal’s data suggests the demand for better remote oversight and automated documentation is deep and widespread. But it also suggests that clinicians are burned out by half-baked solutions that add clicks without subtracting burden. The winner in this space won’t just monitor vertigo. It will make the clinician’s day shorter and the clinic’s revenue cycle tighter.

That’s a pitch worth tracking.